Evidence map›Paper›PMID 41519752›Full record

ArticleBMC microbiology2026

Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo.

Zimo Wang, Yangxue Ye, Weiyan Zhang, Bin Wang, Xiaoyou Chen, Yu Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zimo WangBeijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical university, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yangxue YeBeijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical university, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Weiyan ZhangBeijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical university, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Bin WangBeijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical university, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Xiaoyou ChenBeijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. chenxy1998@hotmail.com.
Yu LuBeijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical university, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China. luyu4876@hotmail.com.

Funding

the Beijing Municipal Administration of Hospitals' Ascent Plan (DFL20221402)
6 · The paper itself

Abstract

backgroundM. abscessus (Mabs) is one of the principal pathogenic strains among nontuberculous mycobacterial. Mabs infections pose a significant global public health challenge, leading to substantial morbidity and mortality. However, a standard treatment regimen has not yet been established. The goal of this study was to provide clear insights into constructing regimens.

methodsWe evaluated the efficacy of 7 clinically available drugs against Mabs under various environments through microplate alamar blue assay (MABA), biofilm assays, Wayne model and nutrient-starvation model. The checkerboard assay was employed to assess drug-drug interactions. Finally, we assessed the efficacy, degree of organ damage, and prevalence of resistant strains associated with different triple-drug combinations in a BALB/c mouse model.

resultsBedaquiline (BDQ) was active against replicating and nonreplicating planktonic bacteria. Moxifloxacin (MFX) was potent in preventing biofilm formation and inhibiting the viability of biofilm-resident bacteria. ABM (Azithromycin-Bedaquiline-Moxifloxacin) and CBM (Clofazimine-Bedaquiline-Moxifloxacin) combinations were effective in bacillary load reduction and organ injury alleviation in BALB/c mouse model.

conclusionsABM and CBM regimens show great promise against Mabs in vivo. We strongly recommend carrying out additional clinical trials to explore their efficacy.

Indexed as

Anti-Bacterial AgentsMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsAzithromycinBiofilmsClofazimineDiarylquinolinesDisease Models, AnimalDrug InteractionsDrug Therapy, CombinationFemaleMiceMice, Inbred BALB CMicrobial Sensitivity TestsMoxifloxacinAnti-Bacterial AgentsAzithromycinbedaquilineClofazimineDiarylquinolinesMoxifloxacinMycobacterial abscessusNontuberculous mycobacterialRegimen

Identifiers

PMID41519752
PMCPMC12918053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.